Glaukos Management
Management criteria checks 3/4
Glaukos' CEO is Tom Burns, appointed in Apr 2002, has a tenure of 22.75 years. total yearly compensation is $8.65M, comprised of 8.8% salary and 91.2% bonuses, including company stock and options. directly owns 2.68% of the company’s shares, worth $221.27M. The average tenure of the management team and the board of directors is 4.3 years and 10.5 years respectively.
Key information
Tom Burns
Chief executive officer
US$8.7m
Total compensation
CEO salary percentage | 8.8% |
CEO tenure | 22.8yrs |
CEO ownership | 2.7% |
Management average tenure | 4.3yrs |
Board average tenure | 10.5yrs |
Recent management updates
Recent updates
Are Investors Undervaluing Glaukos Corporation (NYSE:GKOS) By 50%?
Dec 25Glaukos: Still Bullish, But Embedded Expectations Are Now High
Dec 21Revenues Tell The Story For Glaukos Corporation (NYSE:GKOS)
Dec 03Is Glaukos (NYSE:GKOS) Using Debt In A Risky Way?
Sep 18Glaukos Corporation: Ripe For Some Consolidation
Sep 11Glaukos Corporation's (NYSE:GKOS) Intrinsic Value Is Potentially 81% Above Its Share Price
Aug 28Glaukos Corporation (NYSE:GKOS) Just Reported And Analysts Have Been Lifting Their Price Targets
Aug 07Glaukos Corporation's (NYSE:GKOS) Popularity With Investors Is Clear
Jul 18Glaukos (NYSE:GKOS) Is Carrying A Fair Bit Of Debt
Jun 11Glaukos Stock: Still Unproven Whether A New Bull Market Has Begun
May 30Here's Why Glaukos Corporation's (NYSE:GKOS) CEO Compensation Is The Least Of Shareholders' Concerns
May 24Why Glaukos Corporation (NYSE:GKOS) Could Be Worth Watching
Apr 22Glaukos Corporation (NYSE:GKOS) Not Lagging Industry On Growth Or Pricing
Apr 04Glaukos Corporation's (NYSE:GKOS) Intrinsic Value Is Potentially 69% Above Its Share Price
Feb 21Is Glaukos (NYSE:GKOS) A Risky Investment?
Jan 21Glaukos: Remains A Hold Due To High Valuation And Negative Profitability
Jan 09Glaukos: Continued Growth Rates, Regulatory Tailwinds, And Support
Sep 01Glaukos: Revising To Buy On These 3 Catalytic Factors
Jun 16Glaukos: Trial Momentum Building, Profitability Differentials Yet To Pull Through
Feb 14Glaukos sees positive data from mid-stage trial of dry eye treatment
Jan 10Glaukos: Show Me The Money
Nov 10Glaukos pays $10M upfront to license iVeena's eye disorder therapy IVMED-80
Aug 24CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Sep 30 2024 | n/a | n/a | -US$150m |
Jun 30 2024 | n/a | n/a | -US$159m |
Mar 31 2024 | n/a | n/a | -US$141m |
Dec 31 2023 | US$9m | US$765k | -US$135m |
Sep 30 2023 | n/a | n/a | -US$129m |
Jun 30 2023 | n/a | n/a | -US$126m |
Mar 31 2023 | n/a | n/a | -US$139m |
Dec 31 2022 | US$6m | US$730k | -US$99m |
Sep 30 2022 | n/a | n/a | -US$90m |
Jun 30 2022 | n/a | n/a | -US$56m |
Mar 31 2022 | n/a | n/a | -US$28m |
Dec 31 2021 | US$7m | US$702k | -US$50m |
Sep 30 2021 | n/a | n/a | -US$38m |
Jun 30 2021 | n/a | n/a | -US$60m |
Mar 31 2021 | n/a | n/a | -US$83m |
Dec 31 2020 | US$6m | US$608k | -US$120m |
Sep 30 2020 | n/a | n/a | -US$73m |
Jun 30 2020 | n/a | n/a | -US$71m |
Mar 31 2020 | n/a | n/a | -US$37m |
Dec 31 2019 | US$6m | US$644k | US$15m |
Sep 30 2019 | n/a | n/a | -US$19m |
Jun 30 2019 | n/a | n/a | -US$12m |
Mar 31 2019 | n/a | n/a | -US$12m |
Dec 31 2018 | US$5m | US$625k | -US$13m |
Compensation vs Market: Tom's total compensation ($USD8.65M) is about average for companies of similar size in the US market ($USD7.89M).
Compensation vs Earnings: Tom's compensation has increased whilst the company is unprofitable.
CEO
Tom Burns (63 yo)
22.8yrs
Tenure
US$8,654,684
Compensation
Mr. Thomas William Burns, also known as Tom, has been the Chief Executive Officer at Glaukos Corporation since April 1, 2022 and serves as its Chairman of the Board since December 31, 2021. He had Presiden...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chairman & CEO | 22.8yrs | US$8.65m | 2.68% $ 221.3m | |
President & COO | 2.8yrs | US$4.18m | 0.047% $ 3.9m | |
Senior VP & CFO | 2.8yrs | US$2.36m | 0.052% $ 4.3m | |
Chief Development Officer | 4.3yrs | US$2.57m | 0.048% $ 4.0m | |
Co-Founder | no data | no data | no data | |
Vice President of Investor Relations & Corporate Affairs | no data | no data | no data | |
Senior VP | no data | no data | no data | |
VP of Compliance & Deputy General Counsel | no data | no data | no data | |
Senior Vice President of Human Resources | 9.7yrs | no data | no data | |
Executive Vice President of Global Commercial Operations | 2.8yrs | US$198.66k | no data | |
Chief Medical Officer | no data | no data | no data | |
Senior Vice President of Corporate Strategy & Business Development | 6.8yrs | no data | no data |
4.3yrs
Average Tenure
58yo
Average Age
Experienced Management: GKOS's management team is considered experienced (4.3 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chairman & CEO | 22.8yrs | US$8.65m | 2.68% $ 221.3m | |
Independent Director | 4.8yrs | US$259.00k | 0.054% $ 4.5m | |
Member of Scientific Advisory Board | no data | no data | no data | |
Independent Director | 10.5yrs | US$259.00k | 0.075% $ 6.2m | |
Lead Independent Director | 10.5yrs | US$319.38k | 0.054% $ 4.5m | |
Independent Director | 10.5yrs | US$262.13k | 0.066% $ 5.5m | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Independent Director | 10.5yrs | US$273.39k | 0.050% $ 4.2m | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data |
10.5yrs
Average Tenure
61yo
Average Age
Experienced Board: GKOS's board of directors are seasoned and experienced ( 10.5 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/02 23:18 |
End of Day Share Price | 2025/01/02 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Glaukos Corporation is covered by 25 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Ishan Majumdar | Baptista Research |
Ravi Misra | Berenberg |
Joanne Wuensch | BMO Capital Markets Equity Research |